Drug Monitoring of Antibiotics in the Era of Precision Dosing

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1159

Special Issue Editors


E-Mail Website
Guest Editor
1. Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132 Genoa, Italy
2. Clinical Pharmacology Unit, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
Interests: drug monitoring; antibiotics; precision dosing; pharmacokinetics; pharmacodynamics; PK/PD relationship; clinical pharmacology; clinical pharmacokinetics; population pharmacokinetics

E-Mail Website
Guest Editor
1. Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132 Genoa, Italy
2. Clinical Pharmacology Unit, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
Interests: drug monitoring; antibiotics; precision dosing; pharmacokinetics; pharmacodynamics; PK/PD relationship; clinical pharmacology; population pharmacokinetics; model-informed precision dosing

Special Issue Information

Dear Colleagues,

Drug monitoring of antibiotics is a fundamental tool for the attainment of the PK/PD targets associated with favourable clinical outcomes and a reduction in the toxicity of established and novel drugs. Nowadays, precision dosing of antibiotics is spreading in clinical practice, thanks to the diffusion of gold-standard techniques of drug quantitation like LC-MS/MS. The specific quantification of antibiotics enables the reliable set up of population pharmacokinetic models to guide clinician dosing adjustments in specific patient populations. Expert clinical pharmacologists’ measurement and interpretation of drug concentrations is essential to support the antimicrobial stewardship, along with the informed opinion of fellow infectivologists and microbiologists, to unlock the full clinical benefit of a therapeutic intervention.

In this Special Issue of Pharmaceutics, we aim to publish novel clinical evidence and/or reviews supporting dosing optimization of antibiotic treatments by therapeutic drug monitoring and PK/PD pharmacokinetics principles for precision dosing recommendations.

Dr. Francesca Mattioli
Dr. Giammarco Baiardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug monitoring
  • antibiotics
  • precision dosing
  • TDM-guided dosing
  • PK/PD relationship
  • HPLC
  • LC-MS/MS
  • antimicrobial stewardship
  • clinical pharmacology
  • population pharmacokinetics
  • model-informed precision dosing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1675 KiB  
Article
Pharmacokinetics of Piperacillin–Tazobactam in Critically Ill Patients with Open Abdomen and Vacuum-Assisted Wound Closure: Dosing Considerations Using Monte Carlo Simulation
by Cédric Carrié, Jesse Butruille, Sophie Maingault, Alexandre Lannou, Vincent Dubuisson, Laurent Petit, Matthieu Biais and Dominique Breilh
Pharmaceutics 2024, 16(9), 1191; https://doi.org/10.3390/pharmaceutics16091191 - 9 Sep 2024
Viewed by 753
Abstract
Background: Open abdomen with vacuum-assisted wound closure therapy (OA/VAC) is frequently used in critically ill patients although the impact of OA/VAC on antibiotics pharmacokinetics (PK) remains unknown. We thus aimed to characterize the PK of piperacillin–tazobactam (PTZ) in critically ill patients with OA/VAC [...] Read more.
Background: Open abdomen with vacuum-assisted wound closure therapy (OA/VAC) is frequently used in critically ill patients although the impact of OA/VAC on antibiotics pharmacokinetics (PK) remains unknown. We thus aimed to characterize the PK of piperacillin–tazobactam (PTZ) in critically ill patients with OA/VAC and assess the optimal dosing regimens based on pharmacodynamics (PD) target attainment. Methods: Over a 15-month study period, 45 patients with OA/VAC treated with PTZ administered continuously and adapted to 24 h creatinine clearance (CLCR) underwent measurements of free concentrations in their plasma, urine, VAC exudate, and peritoneal fluid. Population PK modeling was performed considering the effect of covariates, and Monte Carlo simulations were employed to determine the probability of target attainment (PTA) for the PK/PD targets (100% fT > 16 mg/L) in the plasma and at the peritoneal site at steady state. Results: Piperacillin concentrations were described using a two-compartment model, with age and total body weight as significant covariates for central volume of distribution (V1) and estimated renal function for clearance (CL). Tazobactam concentrations were described using a two-compartment model with estimated renal function as a significant covariate. The central volume of distributions V1 of piperacillin and tazobactam were 21.2 and 23.2 L, respectively. The VAC-induced peritoneal clearance was negligible compared to renal clearance. Most patients achieved the desirable PK/PD target when using a CLCR-pondered PTZ dosing regimen from 12 g/1.5 g/day to 20 g/2.5 g/day. Conclusions: Despite a wide inter-individual variability, the influence of OA/VAC on piperacillin and tazobactam PK parameters is not straightforward. The use of a CLCR-pondered PTZ dosing regimen from 12 g/1.5 g/day to 20 g/2.5 g/day is needed to reach a PTA > 85%. Full article
(This article belongs to the Special Issue Drug Monitoring of Antibiotics in the Era of Precision Dosing)
Show Figures

Figure 1

Back to TopTop